<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197000</url>
  </required_header>
  <id_info>
    <org_study_id>0117-14-RMC</org_study_id>
    <nct_id>NCT02197000</nct_id>
  </id_info>
  <brief_title>A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers</brief_title>
  <official_title>A Nutritional Intervention to Decrease Breast Density Among Female BRCA Carriers -A Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adding DIM supplement will decrease breast&#xD;
      density among female BRCA mutation carriers in two years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Research Question: In female BRCA mutation carriers, will adding DIM (100mg*1/d, a&#xD;
      nutritional supplement), decrease breast density in two years?&#xD;
&#xD;
      Study design: A single center single arm prospective interventional study of the use of DIM&#xD;
      to decrease risk of breast cancer among female BRCA carriers.&#xD;
&#xD;
      Study population: Subjects will be female carriers of a BRCA mutation and have more than 10%&#xD;
      mammographic breast density at baseline.&#xD;
&#xD;
      Intervention: DIM supplement (100mg*1/d).&#xD;
&#xD;
      Study Time line: This will be a 2 years study. At initiation a breast mammography will be&#xD;
      performed and eligibility assessed. Follow-up visits will occur every 4 months and quality of&#xD;
      life questionnaires as well as adherence to DIM supplementation will be assessed. At the&#xD;
      initiation and every 4 months blood and urine samples will be collected for Estrogen profile.&#xD;
      At 12 and 24 months a mammography will be performed to verify changes in breast density.&#xD;
&#xD;
      Primary Endpoint: A decrease of more than 10% in breast density compared to baseline,&#xD;
      following DIM supplementation intervention among female BRCA carriers.&#xD;
&#xD;
      Study impact: Decrease in mammographic breast density was shown to be a good marker for lower&#xD;
      risk of breast cancer. This study has the potential to dramatically impact the management of&#xD;
      female BRCA carriers. If we prove that by adding a food supplement breast density is&#xD;
      decreased, we will change standard of care in these woman. In addition, the urine and blood&#xD;
      samples collected during the study will be used for future translational research on the&#xD;
      pathogenesis of breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2014</start_date>
  <completion_date type="Actual">October 10, 2018</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in breast density compared to baseline</measure>
    <time_frame>0, 12 and 24 months following intiation</time_frame>
    <description>The amount of fibroglandular tissue (FGT) and background parenchymal enhancement (BPE) on magnetic resonance imaging (MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estrogen profile</measure>
    <time_frame>0, 4, 8, 12, 16 and 24 months following initiation</time_frame>
    <description>changes in TSH (Thyroid Stimulating Hormone), FSH (Follicle Stimulating Hormone), LH (Luteinizing Hormone), Estrogen, Prolactin, Progesterone and Testosterone compare to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Estronex Profile</measure>
    <time_frame>0, 12 and 24 months following initiation</time_frame>
    <description>changes in the 2, 4, and 16 alpha- hydroxyderivative of estrone and the 2 and 4 methoxyestrone compare to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Quality of life</measure>
    <time_frame>0, 4, 8, 12, 16 and 24 months following initiation</time_frame>
    <description>Quality of life will be evaluate using the Revised Illness Perception Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>BRCA1 Gene Mutation</condition>
  <condition>BRCA2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>DIM-Avail 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women will receive DIM 100mg*1/d, a nutritional supplement for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DIM-Avail 100mg</intervention_name>
    <description>DIM 100 mg*1 daily for 2 years</description>
    <arm_group_label>DIM-Avail 100mg</arm_group_label>
    <other_name>3,3-Diindolylmethane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who carrier the BRCA 1\2 mutation.&#xD;
&#xD;
          -  No history of breast or ovarian malignancy.&#xD;
&#xD;
          -  i. Baseline mammographic breast density is more than 10% OR ii. Baseline breast MRI&#xD;
             with density or enhancement â‰¤ 2.&#xD;
&#xD;
          -  Age 18-70.&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical situation&#xD;
             potentially hampering adherence to the study protocol and follow-up schedule.&#xD;
&#xD;
          -  Informed written consent must be signed according to ICH/EU GCP, before subject&#xD;
             registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who have undergone preventive breast reduction.&#xD;
&#xD;
          -  Breast imaging demonstrating a lesion suspected to be cancerous.&#xD;
&#xD;
          -  Breast feeding or Pregnancy or planning to get pregnant.&#xD;
&#xD;
          -  Known allergy to DIM and its ingredients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Margel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center, Beilinson campus, Petah-Tikva, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rinat Yerushalmi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 20, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA mutation</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Estrogen metabolism</keyword>
  <keyword>3,3-Diindolylmethane</keyword>
  <keyword>Breast density</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,3'-diindolylmethane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

